Page last updated: 2024-12-09
cis-isrib
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 1011240 |
| CHEMBL ID | 4303573 |
| SCHEMBL ID | 16082980 |
| SCHEMBL ID | 16083047 |
| SCHEMBL ID | 16082988 |
| MeSH ID | M000607381 |
Synonyms (66)
| Synonym |
|---|
| STK435431 |
| n,n'-cyclohexane-1,4-diylbis[2-(4-chlorophenoxy)acetamide] |
| OPREA1_706389 |
| 2-(4-chlorophenoxy)-n-[4-[[2-(4-chlorophenoxy)acetyl]amino]cyclohexyl]acetamide |
| AKOS003300916 |
| S7400 |
| isrib (trans-isomer) |
| c22h24cl2n2o4 |
| isrib |
| SCHEMBL16082980 |
| SCHEMBL16083047 |
| SCHEMBL16082988 |
| 1597403-47-8 |
| trans-isrib |
| AKOS025142075 |
| n,n'-trans-1,4-cyclohexanediylbis[2-(4-chlorophenoxy)acetamide] |
| AC-35228 |
| n,n'-((1r,4r)-cyclohexane-1,4-diyl)bis(2-(4-chlorophenoxy)acetamide) |
| 548470-11-7 |
| J-690321 |
| EX-A298 |
| 2-(4-chlorophenoxy)-n-{4-[2-(4-chlorophenoxy)acetamido]cyclohexyl}acetamide |
| 2-(4-chlorophenoxy)-n-[(1r,4r)-4-[2-(4-chlorophenoxy)acetamido]cyclohexyl]acetamide |
| trans-isomer |
| isrib trans-isomer |
| mfcd27952932 |
| isrib, >=98% (hplc) |
| NCGC00389802-01 |
| AKOS030633038 |
| n,n'-(cis-cyclohexane-1,4-diyl)bis(2-(4-chlorophenoxy)acetamide) |
| 1597403-48-9 |
| C7B , |
| 2-(4-chloranylphenoxy)-~{n}-[4-[2-(4-chloranylphenoxy)ethanoylamino]cyclohexyl]ethanamide |
| BCP23947 |
| n,n'-(cyclohexane-1,4-diyl)bis(2-(4-chlorophenoxy)acetamide) |
| FT-0700328 |
| cis-isrib |
| mfcd30730068 |
| DS-19940 |
| AS-16593 |
| BCP10786 |
| cis-isrib;isrib |
| isrib (cis-isomer) |
| A14302 |
| n,n'-(trans-cyclohexane-1,4-diyl)bis(2-(4-chlorophenoxy)acetamide) |
| acetamide, n,n'-trans-1,4-cyclohexanediylbis[2-(4-chlorophenoxy)- |
| NCGC00384174-11 |
| HMS3887M19 |
| n,n'-(cis-cyclohexane-1,4-diyl)bis(2-(4-chlorophenoxy)acetamide |
| CCG-269245 |
| CHEMBL4303573 |
| C73020 |
| A897811 |
| n,n'-1,4-cyclohexanediylbis[2-(4-chlorophenoxy)acetamide] |
| isrib(trans-isomer) |
| AS-55833 |
| XNC40347 |
| XNC40348 |
| CS-0187553 |
| S0706 |
| trans-n,n'-(cyclohexane-1,4-diyl)bis(2-(4-chlorophenoxy)acetamide) |
| A899328 |
| 2-(4-chlorophenoxy)-n-[(1s,4s)-4-[2-(4-chlorophenoxy)acetamido]cyclohexyl]acetamide |
| DTXSID601045380 |
| HY-12495A |
| CS-0029263 |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (7)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.72
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.72) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||